ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Prof Li talks about the new findings with the drug metformin in diabetic patients with pancreatic cancer. Preliminary data has shown that 117 patients who use metformin showed a 4-month increase in overall survival and 18 percent increase in first year survival.
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Enhancing head and neck oncology: Key insights from the conference
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Choosing 1st line TKI Wisely in patients with CML